FIELD: chemistry.
SUBSTANCE: invention relates to a compound of formula (I), in which L is NR2R3; R2 is hydrogen or unsubstituted alkyl; R3 represents substituted alkyl, unsubstituted alkenyl, unsubstituted aryl, substituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclyl, substituted carbonyl or substituted arylsulfonyl; Y is a substituted heterocyclyl, which is
, where R9 is hydrogen; R10 is a hydroxy, substituted or unsubstituted C1-C6alkyloxy or heterocyclyloxy; m denotes integer 0; Z is -N=; R1 is hydrogen; R4 is hydrogen, halogen, cyano or haloalkyl; R5 is hydrogen; values of remaining radicals are specified in the claim. Invention also relates to a pharmaceutical composition, to a method for preventing or treating diabetes, to individual compounds, to compounds of formula (IIIa) or (IIIb).
EFFECT: technical result is obtaining novel compounds having an activating adenosine monophosphatactivated protein kinase and can be used in treating diabetes.
13 cl, 76 tbl, 21 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMIDZOL DERIVATIVE CONDENSED HETEROCYCLE HAVING ACTIVE AMPK EFFECT | 2011 |
|
RU2635662C2 |
| TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION INCLUDING IT, POSSESSING ANALGESIC ACTIVITY | 2011 |
|
RU2565073C2 |
| MONOMER DERIVATIVES OF GLYCOPEPTIDE ANTIBIOTIC | 2005 |
|
RU2424248C2 |
| HETEROCYCLIC DERIVATIVE WITH AROMATIC 5-MEMBER CYCLE POSSESSING NPY Y5 RECEPTOR ANTAGONIST ACTIVITY | 2012 |
|
RU2605207C2 |
| SYNTHESIS OF THIAZOLIDINEDIONE COMPOUNDS | 2011 |
|
RU2594725C2 |
| PYRIDAZINE DERIVATIVE INHIBITOR, METHOD OF ITS PREPARATION AND ITS USE | 2020 |
|
RU2807611C2 |
| HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | 2017 |
|
RU2742115C2 |
| NEW METHOD FOR SYNTHESIS OF THIAZOLIDINEDIONE COMPOUNDS | 2011 |
|
RU2593370C2 |
| COMBINED THERAPY INCLUDING SGLT INHIBITORS AND DPP4 INHIBITORS | 2009 |
|
RU2481106C2 |
| HETEROCYCLIC COMPOUNDS HAVING 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITING ACTIVITY | 2006 |
|
RU2443689C2 |
